The promise of the second-generation drug dasatinib against pediatric CML has been demonstrated in a new study. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib.